$8.200
-0.050 (-0.61%)終値時点
PRTA の収益性とマージン
Evaluating the bottom line, Prothena Corporation PLC maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1850.20%, while the net margin is -1839.90%. These profitability ratios, combined with a Return on Equity (ROE) of -14.39%, provide a clear picture of how effectively PRTA converts its operational activities into shareholder value.
PRTA の同業比較
In the context of the broader market, PRTA competes directly with industry leaders such as ALT and CBIO. With a market capitalization of $428.66M, it holds a significant position in the sector. When comparing efficiency, PRTA's gross margin of 100.00% stands against ALT's N/A and CBIO's 100.00%. Such benchmarking helps identify whether Prothena Corporation PLC is trading at a premium or discount relative to its financial performance.
Prothena Corporation PLC の財務パフォーマンス
Prothena's financial performance shows a significant improvement in Q1 2026 with a net income of 32.72 million USD, compared to substantial losses in previous quarters. The gross margin remains strong at 100%, reflecting efficient cost management. However, the company has a negative P/E ratio of -9.63, indicating that it is currently not profitable overall.
Financials
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。